JP2004524357A - プレガバリンラクトース結合体 - Google Patents

プレガバリンラクトース結合体 Download PDF

Info

Publication number
JP2004524357A
JP2004524357A JP2002577011A JP2002577011A JP2004524357A JP 2004524357 A JP2004524357 A JP 2004524357A JP 2002577011 A JP2002577011 A JP 2002577011A JP 2002577011 A JP2002577011 A JP 2002577011A JP 2004524357 A JP2004524357 A JP 2004524357A
Authority
JP
Japan
Prior art keywords
tetrahydro
pyran
pyrrolidin
isobutyl
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002577011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524357A5 (OSRAM
Inventor
ティモシー・ロバート・ハーリー
マイクル・ジェイムズ・ローヴダール
ブライアン・トバイアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2004524357A publication Critical patent/JP2004524357A/ja
Publication of JP2004524357A5 publication Critical patent/JP2004524357A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002577011A 2001-03-30 2002-02-25 プレガバリンラクトース結合体 Pending JP2004524357A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30
PCT/IB2002/000647 WO2002078747A2 (en) 2001-03-30 2002-02-25 Pregabalin lactose conjugates

Publications (2)

Publication Number Publication Date
JP2004524357A true JP2004524357A (ja) 2004-08-12
JP2004524357A5 JP2004524357A5 (OSRAM) 2005-12-22

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002577011A Pending JP2004524357A (ja) 2001-03-30 2002-02-25 プレガバリンラクトース結合体

Country Status (32)

Country Link
US (1) US7022678B2 (OSRAM)
EP (1) EP1377318A2 (OSRAM)
JP (1) JP2004524357A (OSRAM)
KR (1) KR20040008146A (OSRAM)
CN (1) CN1511043A (OSRAM)
AP (1) AP2003002873A0 (OSRAM)
AR (1) AR033024A1 (OSRAM)
BG (1) BG108193A (OSRAM)
BR (1) BR0208439A (OSRAM)
CA (1) CA2440468C (OSRAM)
CZ (1) CZ20032547A3 (OSRAM)
DO (1) DOP2002000356A (OSRAM)
EA (1) EA200300954A1 (OSRAM)
EC (1) ECSP034740A (OSRAM)
EE (1) EE200300480A (OSRAM)
GT (1) GT200200051A (OSRAM)
HU (1) HUP0303956A2 (OSRAM)
IL (1) IL157879A0 (OSRAM)
IS (1) IS6912A (OSRAM)
MA (1) MA27004A1 (OSRAM)
MX (1) MXPA03007437A (OSRAM)
NO (1) NO20034348D0 (OSRAM)
OA (1) OA12456A (OSRAM)
PA (1) PA8542101A1 (OSRAM)
PE (1) PE20021016A1 (OSRAM)
PL (1) PL369179A1 (OSRAM)
SK (1) SK11832003A3 (OSRAM)
SV (1) SV2003000928A (OSRAM)
TN (1) TNSN02038A1 (OSRAM)
UY (1) UY27233A1 (OSRAM)
WO (1) WO2002078747A2 (OSRAM)
ZA (1) ZA200306608B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
WO2007035890A1 (en) 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010115612A2 (en) 2009-04-10 2010-10-14 Synthon B.V. Pregabalin compositions
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
KR100697734B1 (ko) * 1998-10-16 2007-03-22 워너-램버트 캄파니 엘엘씨 조증 및 양극성 장애 치료용 제약 조성물
IL155704A0 (en) * 2000-11-30 2003-11-23 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
US7022678B2 (en) 2006-04-04
WO2002078747A8 (en) 2003-12-04
IS6912A (is) 2003-08-14
BG108193A (en) 2004-09-30
PA8542101A1 (es) 2002-10-28
KR20040008146A (ko) 2004-01-28
US20020187941A1 (en) 2002-12-12
WO2002078747A2 (en) 2002-10-10
AP2003002873A0 (en) 2003-09-30
UY27233A1 (es) 2002-10-31
AR033024A1 (es) 2003-12-03
PL369179A1 (en) 2005-04-18
TNSN02038A1 (fr) 2005-12-23
OA12456A (en) 2004-08-24
PE20021016A1 (es) 2002-11-14
CA2440468C (en) 2008-09-02
MXPA03007437A (es) 2003-11-18
EA200300954A1 (ru) 2004-02-26
NO20034348L (no) 2003-09-29
ECSP034740A (es) 2003-12-24
WO2002078747A3 (en) 2003-10-09
EE200300480A (et) 2003-12-15
MA27004A1 (fr) 2004-12-20
EP1377318A2 (en) 2004-01-07
SK11832003A3 (sk) 2004-04-06
CN1511043A (zh) 2004-07-07
ZA200306608B (en) 2004-11-25
SV2003000928A (es) 2003-07-29
CA2440468A1 (en) 2002-10-10
BR0208439A (pt) 2004-03-23
DOP2002000356A (es) 2002-12-15
CZ20032547A3 (en) 2004-04-14
NO20034348D0 (no) 2003-09-29
HUP0303956A2 (hu) 2004-04-28
GT200200051A (es) 2002-11-15
WO2002078747A9 (en) 2003-12-31
IL157879A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
DE69629670T2 (de) Lactam-enthaltende hydroxamsäure-derivate, deren herstellung und deren verwendung als inhibitoren von matrix-metalloproteasen
Bodor et al. Improved delivery through biological membranes. 13. Brain-specific delivery of dopamine with a dihydropyridine. dblharw. pyridinium salt type redox delivery system
US7022678B2 (en) Pregabalin lactose conjugates
CN100536851C (zh) 丙戊酸的磷脂衍生物及其混合物
JP3004297B2 (ja) リゾスフィンゴ脂質誘導体
ES3060711T3 (en) 3-hydroxy-5-pregnane-20-one derivative and use thereof
HUE034562T2 (en) Polymixins, preparations, methods of preparation and methods of application
US12391662B2 (en) Lipid compounds and lipid nanoparticle compositions
JP2025523693A (ja) 安定なシロシン塩、エステルおよび抱合体の調製およびそれらの使用
EP0381070A1 (en) Synthetic amphiphilic glycoconjugates for neurological use
JP7750582B2 (ja) 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途
JP2004517939A (ja) 初期アルツハイマー病の予防および治療に用いられるクリプトタンシノン
KR102750784B1 (ko) 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 제조방법 및 그 중간체
EP2269980A1 (de) Creatinamide, verfahren zu ihrer herstellung und wirkstoff zur ausführung einer neuroprotektiven aktion
EP3349853B1 (en) Prodrugs of fencamfamine
US20220000814A1 (en) Methods for treatment of prader-willi syndrome
CN119523898A (zh) 多靶点药物的经鼻给药制剂及其应用
JP2022510480A (ja) ドーパミン応答性障害の治療のための糖にコンジュゲートされたｌ－ｄｏｐａ及び／またはｄｏｐａデカルボキシラーゼ阻害剤
CN102250066B (zh) 法舒地尔衍生物及其制备方法
AU2002236134A1 (en) Pregabalin lactose conjugates
CN102439022A (zh) 新型钠通道阻滞化合物河豚毒素吡喃半乳糖苷
EP1064294B1 (en) 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
US11701338B2 (en) Use of gTso thal in manufacturing medicament for promotion of MS-275 to cross blood-brain barrier
US6608080B1 (en) Morphan derivatives or salts thereof and medicinal compositions containing the same
ES3041301T3 (en) Pharmaceutical composition comprising benzocaine with enhanced stability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050225

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081106

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090406